American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch
Daiichi Sankyo Affiliate Holds 505(b)(2) NDA Approval For Vasostrict Rival
Executive Summary
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.
You may also be interested in...
Eagle Vindicated On Vasopressin With US Federal Circuit Decision
Endo’s woes show no sign of abating, with the US Court of Appeals for the Federal Circuit shooting down its appeal against a finding of non-infringement for two key patents shielding its Vasostrict injectable.
Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring
A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.
What’s Next? Five Things To Look Out For In July
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.